Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP lowered its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 32.1% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 4,985,976 shares of the company’s stock after selling 2,353,028 shares during the period. Wellington Management Group LLP owned 0.06% of Syndax Pharmaceuticals worth $95,980,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. BNP PARIBAS ASSET MANAGEMENT Holding S.A. acquired a new stake in shares of Syndax Pharmaceuticals during the third quarter worth $15,165,000. Eventide Asset Management LLC acquired a new stake in Syndax Pharmaceuticals during the 3rd quarter worth about $15,150,000. First Turn Management LLC purchased a new stake in Syndax Pharmaceuticals during the second quarter valued at about $13,147,000. Sofinnova Investments Inc. boosted its holdings in shares of Syndax Pharmaceuticals by 33.9% in the second quarter. Sofinnova Investments Inc. now owns 2,153,669 shares of the company’s stock worth $44,215,000 after buying an additional 545,129 shares during the period. Finally, Millennium Management LLC increased its position in shares of Syndax Pharmaceuticals by 56.3% in the second quarter. Millennium Management LLC now owns 1,065,508 shares of the company’s stock worth $21,875,000 after acquiring an additional 383,634 shares in the last quarter.

Syndax Pharmaceuticals Stock Performance

NASDAQ SNDX opened at $15.56 on Tuesday. Syndax Pharmaceuticals, Inc. has a twelve month low of $15.00 and a twelve month high of $25.34. The stock has a market cap of $1.33 billion, a PE ratio of -4.29 and a beta of 0.86. The firm has a 50-day simple moving average of $18.22 and a 200 day simple moving average of $19.62.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.15. The business had revenue of $12.50 million during the quarter, compared to analyst estimates of $9.16 million. During the same quarter in the prior year, the company posted ($0.73) EPS. Research analysts forecast that Syndax Pharmaceuticals, Inc. will post -2.39 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently commented on SNDX. UBS Group started coverage on shares of Syndax Pharmaceuticals in a research report on Thursday, October 24th. They issued a “buy” rating and a $37.00 price target for the company. The Goldman Sachs Group increased their target price on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a report on Thursday, November 7th. HC Wainwright lifted their price target on Syndax Pharmaceuticals from $49.00 to $51.00 and gave the company a “buy” rating in a report on Monday, November 18th. StockNews.com downgraded Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 23rd. Finally, Stifel Nicolaus lifted their target price on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the company a “buy” rating in a research note on Monday, October 14th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $37.64.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).